Remdesivir close to EU's initial authorisation as Covid-19 treatment
Sign up now: Get ST's newsletters delivered to your inbox
Follow topic:
BRUSSELS (REUTERS) - The head of the European Union's medicines agency Guido Rasi said on Monday (May 18) an initial authorisation for US pharmaceutical company Gilead's remdesivir as a Covid-19 treatment could be granted in the coming days.
The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised.
"It might be that a conditional market authorisation can be issued in the coming days," Rasi told a hearing in the EU Parliament in Brussels.
Apart from remdesivir, Rasi said other possible treatments against Covid-19 that may be available fast are those based on monoclonal antibodies, which can "neutralise" the new coronavirus (Sars-CoV-2) that causes the illness COVID-19.
